Ms. Kathryn M. Muilenburg Profile

Kathryn M. Muilenburg

at Univ of Nebraska Medical Ctr

SPIE Involvement:

Author

Publications (1)

This will count as one of your downloads.

You will have access to both the presentation and article (if available).

DOWNLOAD NOW

This content is available for download via your institution's subscription. To access this item, please sign in to your personal account.

Email or Username Forgot your username?

Password Forgot your password?

Show

Keep me signed in

No SPIE account? Create an account

Proceedings Article | 13 March 2024 Presentation + Paper

Targeting mucins for fluorescence-guided surgery of pancreatic cancer

Kathryn Muilenburg, Evie Ehrhorn, Aaron Mohs

Proceedings Volume 12825, 1282503 (2024) https://doi.org/10.1117/12.3009900

KEYWORDS: Pancreatic cancer, Tumors, Chemotherapy, Surgery, Resection, Proteins, Antibodies, Cancer, Diseases and disorders, Tissues

Read Abstract +

Mucins are a family of glycoproteins that have recently been the focus of intense investigation for fluorescence-guided surgery of cancer due to their overexpression in many malignancies. In pancreatic cancer alone there are at least twelve mucins that are upregulated or uniquely expressed. In our group, we have been developing a near infrared fluorescent labelled mAb, NIRF-AR9.6, that targets MUC16, which is overexpressed in 60-80% of pancreatic cancers. We have previously reported that in an orthotopic xenograft model of pancreatic cancer, NIRF-AR9.6 resulted in a 3.7-fold enhancement of tumor compared to surrounding pancreas, while the isotype IgG control resulted in a 2-fold increase. We also demonstrated that NIRF-AR9.6 could enhance PDAC xenografts, even with lower levels of MUC16. Moreover, initial studies showed that NIRF-AR9.6 could enhance a PDX pancreatic cancer model, consistent with MUC16 staining throughout the tumor. We are now investigating the feasibility for NIRF-AR9.6 for fluorescence-guided surgery after neoadjuvant therapy, implementing orthotopic PDX models of varying MUC16 expression, and investigating targeting multiple mucins to account for tumor heterogeneity.

My Library

You currently do not have any folders to save your paper to! Create a new folder below.

Folder Name

Folder Description

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks. You are receiving this notice because your organization may not have SPIE eBooks access.*

*Shibboleth/Open Athens users─please sign in to access your institution's subscriptions.

To obtain this item, you may purchase the complete book in print or electronic format on SPIE.org.

ORGANIZATIONAL
Sign in with credentials provided by your organization.

Organizational Username

Organizational Password

Show/Hide Password

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

;

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members:

Non-members: ADD TO CART

Keywords/Phrases

Search In:

Publication Years